Previous Article | Next Article 
J Virol, March 1998, p. 1775-1781, Vol. 72, No. 3
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Phosphatidylinositol-Dependent Membrane Fusion
Induced by a Putative Fusogenic Sequence of Ebola Virus
M. Begoña
Ruiz-Argüello,
Félix M.
Goñi,
Francisca B.
Pereira, and
José L.
Nieva*
Grupo de Biomembranas (Unidad Asociada al
CSIC), Departamento de Bioquímica, Universidad del
País Vasco, 48080 Bilbao, Spain
Received 16 September 1997/Accepted 20 November 1997
 |
ABSTRACT |
The membrane-interacting abilities of three sequences representing
the putative fusogenic subdomain of the Ebola virus transmembrane protein have been investigated. In the presence of calcium, the sequence EBOGE (GAAIGLAWIPYFGPAAE) efficiently fused
unilamellar vesicles composed of phosphatidylcholine,
phosphatidylethanolamine, cholesterol, and phosphatidylinositol (molar
ratio, 2:1:1:0.5), a mixture that roughly resembles the lipid
composition of the hepatocyte plasma membrane. Analysis of the lipid
dependence of the process demonstrated that the fusion activity of
EBOGE was promoted by phosphatidylinositol but not by other
acidic phospholipids. In comparison, EBOEA
(EGAAIGLAWIPYFGPAA) and EBOEE (EGAAIGLAWIPYFGPAAE) sequences, which are similar to EBOGE except that they bear
the negatively charged glutamate residue at the N terminus and at both
the N and C termini, respectively, induced fusion to a lesser extent.
As revealed by binding experiments, the glutamate residue at the N
terminus severely impaired peptide-vesicle interaction. In addition,
the fusion-competent EBOGE sequence did not associate significantly with vesicles lacking phosphatidylinositol. Tryptophan fluorescence quenching by vesicles containing brominated phospholipids indicated that the EBOGE peptide penetrated to the acyl
chain level only when the membranes contained phosphatidylinositol. We
conclude that binding and further penetration of the Ebola virus
putative fusion peptide into membranes might be governed by the nature
of the N-terminal residue and by the presence of phosphatidylinositol
in the target membrane. Moreover, since insertion of such a peptide
leads to membrane destabilization and fusion, the present data would be
compatible with the involvement of this sequence in Ebola virus fusion.
 |
INTRODUCTION |
Ebola virus belongs to the
Filoviridae family (23). This human pathogen
occasionally causes epidemics of African hemorrhagic fever with a high
rate of mortality (8, 23, 37). Little is known about the
viral infectivity mechanism, and there is no specific treatment for
Ebola virus hemorrhagic fever as yet. The most prominent pathology of
Ebola virus infection includes necrosis of liver parenchyma as a direct
consequence of virus replication (23). Ebola virus virions
are composed of a helical nucleocapsid containing one linear,
negative-sense, single-stranded RNA and surrounded by a lipidic
envelope derived from the host cell plasma membrane (8, 23).
The envelope contains solely one type of highly glycosylated protein
(Ebola GP) arranged into oligomers, most probably trimers, which
constitute the spikes that protrude from the virion surface (8,
30, 38, 39).
The mode of entry of Ebola virus into target cells remains unknown.
However it seems likely that the single surface protein Ebola GP is
responsible for both receptor binding and membrane fusion during entry
into the host cells. Homology analysis of its coding gene-derived
sequence has identified several structural features that Ebola GP
shares with other envelope fusion proteins derived from oncogenic
retroviruses (12, 39). Just recently a detailed analysis has
detected a high degree of structural homology between Ebola GP
and the Rous sarcoma virus transmembrane protein (12).
Several structural elements that might be involved in the
ectodomain fusogenic function are shared by these viruses. In
particular, there exists in both viruses an amino acid region bounded
by cysteines that has at its center a sequence of approximately 16 uncharged and hydrophobic residues. Its location with respect to the
viral membrane, the presence of a canonical fusion tripeptide (YFG in
Ebola virus), and the fact that this sequence exhibits a high degree of
identity among the Filoviridae members suggest that this
region might constitute in Ebola virus the fusion peptide that is
critical for virion-membrane fusion in the Retroviridae and
other families (11, 40, 41).
According to the most widely accepted mechanistic model proposed for
the initial phase of the viral fusion process, activation of the viral
spikes induces the exposure of previously buried hydrophobic fusion
peptides in the vicinity of the target cell (5, 43). Further
interaction of the viral fusion peptides with the cell membrane would
depend mainly on the capacity for binding of these peptides to the
membrane lipid components and could eventually trigger the process that
brings about the actual merging of the viral and cell membranes via a
currently unknown mechanism (41). This fact has justified
the development of in vitro studies on the membrane-destabilizing
effects of fusion peptides by using representative synthetic peptides
of different viruses and model membranes (7, 15, 19, 29).
The membrane environment into which the fusion peptide should partition
obviously plays an important role in the process. Previous work from
this laboratory has focused on the effect of the target membrane
composition on viral fusion. Reports from this and other laboratories
indicate the existence of conformational changes induced by lipidic
components in the membrane-bound human immunodeficiency virus type 1 (HIV-1) fusion peptide (25, 28, 29), and we have identified
a fusogenic conformation of the peptide represented by an extended
-type structure (25, 26, 28). The fusogenic interaction
of the HIV-1 fusion peptide is, moreover, sensitive to factors that
affect gp41 activity in vivo (27). Modulation of viral
fusion by lipids has also been observed for complete virions and
reconstituted systems fusing with model membranes (6, 24,
42). These observations indicate that enveloped viruses may
optimize host interactions during the entry process, not only at the
level of the selective binding to cell receptors but also at the level
of the envelope fusion and subsequent capsid penetration.
Our primary objective in this study was to confirm that the proposed
fusogenic sequence for Ebola virus might interact with membranes,
destabilize them, and eventually induce fusion. Because Ebola virus
infects and replicates very efficiently in the liver, we initially
employed as target membranes large unilamellar vesicles (LUV) made of a
lipidic mixture that represents the hepatocyte plasma membrane
composition (18). Our results demonstrate that this Ebola
virus peptide interacts with phosphatidylinositol (PI)-containing membranes and induces vesicle fusion. Moreover, we show that the sequence lacking the negatively charged Glu residue at the N terminus interacts more efficiently with membranes. These data suggest that,
similarly to the HIV-1 fusion peptide (26-28), the Ebola virus peptide segment under study may be important in viral fusion in
vivo.
 |
MATERIALS AND METHODS |
Materials.
Phosphatidylcholine (PC),
phosphatidylethanolamine (PE), phosphatidic acid (PA), and
phosphatidylglycerol (PG) were from Lipid Products (South
Nutfield, England). PI, the brominated phospholipids 1-palmitoyl-2-stearoyl(6,7)dibromo-sn-glycero-3-phosphocholine (Br6-PSPC) and
1-palmitoyl-2-stearoyl(11,12)dibromo-sn-glycero-3-phosphocholine (Br11-PSPC), and the fluorescent probes
N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)phosphatidylethanolamine (N-NBD-PE) and N-(lissamine rhodamine B
sulfonyl)phosphatidylethanolamine (N-Rh-PE) were purchased from Avanti
Polar Lipids (Birmingham, Ala.) N-(5-Dimethylaminonaphtalene-1-sulfonyl)-1,2-dihexadecanoyl-sn-glyc- ero-3-phosphoethanolamine
(d-DHPE) was from Molecular Probes (Junction City, Oreg.).
Cholesterol (CHOL), trinitrophenylphosphatidylethanolamine (TNP-PE),
and Triton X-100 were obtained from Sigma (St. Louis, Mo.). All
other reagents were of analytical grade. The sequences representing the putative fusogenic segment of Ebola GP, i.e., EBOGE, EBOEA, and EBOEE (see Fig.
1A), were synthesized as their C-terminal carboxamides and
purified (estimated homogeneity, >90%) by Quality Controlled
Biochemicals, Inc. (Hopkinton, Mass.). Peptide stock solutions
were prepared in dimethyl sulfoxide (spectroscopy grade).
Vesicle preparation.
LUV were prepared by the extrusion
method of Hope et al. (17) in 5 mM HEPES-100 mM NaCl (pH
7.4) buffer. Small unilamellar vesicles (SUV) were obtained by
sonication of aqueous lipid dispersions (2). Lipid
concentrations in liposome suspensions were determined by phosphate
analysis (4).
Fluorimetric assay for vesicle fusion.
All fluorescence
measurements were conducted in thermostatically controlled cuvettes
(37°C) with a Perkin-Elmer LS50-B spectrofluorimeter. The medium in
the cuvettes was continuously stirred to allow the rapid mixing of
peptide and vesicles. Membrane lipid mixing was monitored by using the
resonance energy transfer assay described by Struck et al.
(35). The assay is based on the dilution of N-NBD-PE and
N-Rh-PE. Dilution due to membrane mixing results in an increase in
N-NBD-PE fluorescence. Vesicles containing each probe at 0.6 mol% were
mixed with unlabeled vesicles at a 1:4 ratio (final lipid
concentration, 0.1 mM). The NBD emission was monitored at 530 nm, with
the excitation wavelength set at 465 nm. A cutoff filter at 515 nm was
used between the sample and the emission monochromator to avoid
scattering interferences. The fluorescence scale was calibrated such
that the zero level corresponded to the initial residual fluorescence
of the labeled vesicles and the 100% value corresponded to complete
mixing of all the lipids in the system. The latter value was set by the fluorescence intensity of vesicles, labeled with 0.12 mol% of each
fluorophore, at the same total lipid concentration as in the fusion
assay. A high peptide-to-lipid ratio (1:1.5 unless otherwise stated)
was used in these studies in order to maximize vesicle damage, thus
facilitating its detection and study.
Peptide binding to vesicles.
Peptide binding to SUV was
estimated by using three complementary methods under conditions
otherwise similar to those described for the fusion assay. For the
centrifugation method, peptides were added to 1 ml of SUV (0.5 mM)
prepared in buffer (peptide-to-lipid ratio, 1:500). After incubation of
the mixture for 10 min at 37°C, centrifugation of the peptide-lipid
complexes in a Beckman Optima TLX ultracentrifuge in a TL120.2 rotor
(627,000 × g, 90 min, 25°C) gave rise to a lipidic
pellet (>95% of total lipid in the sample). Supernatants depleted of
vesicles were carefully removed, and their peptide content was
subsequently quantitated by Trp fluorescence (excitation at 280 nm and
emission at 350 nm). The percentage of peptide bound to vesicles was
estimated by using the following expression:
|
(1)
|
where F(s
l)
represents Trp fluorescence emission intensity in supernatants of
centrifuged peptides in the absence of vesicles and
F(s + l) represents Trp
fluorescence in supernatants of centrifuged peptide-vesicle mixtures.
An additional method to evaluate binding was based on the variation of
the fluorescence emitted by Trp. The change in peptide
Trp fluorescence
after binding (1 µM peptide) was measured in
emission spectra
collected in the presence of SUV (0.5 mM). The
mixture was incubated
for 10 min at 37°C before data acquisition.
Excitation was set at 280 nm, and slits of 2.5 nm (excitation)
and 10 nm (emission) were used.
The signal was corrected for inner
filter effects as described
previously (
3). Binding was also
estimated by using an assay
of resonance energy transfer from
peptide-Trp to the headgroup in
TNP-PE as described by Heymann
et al. (
16). TNP-PE was
included in the target vesicle composition
to 8.4 mol%. In the
presence of TNP-PE-containing vesicles (0.5
mM), the decrease of
peptide Trp fluorescence (1 µM peptide) was
measured from emission
spectra collected under the conditions
described above.
Peptide insertion.
The depth of penetration into the
membrane was evaluated by two complementary assays. In order to probe
the interface, energy transfer from peptide Trp to the surface
fluorescent probe d-DHPE was measured as described previously
(13). In brief, 6 mol% d-DHPE probe was included in the
target vesicle composition (0.25 mM), and its emission spectra at
increasing peptide concentrations were collected (maximum emission
wavelength, 510 nm). The excitation wavelength was that of the Trp
residue (280 nm). For probing the acyl chain region, quenching of
peptide Trp fluorescence by the hydrophobic matrix-residing bromolipids
was measured as described previously (3). In this case,
either Br6-PSPC or Br11-PSPC was used instead
of PC in target PC-PI (1:2 molar ratio) vesicles. Trp emission spectra
(1 µM peptide) were acquired in the presence of the vesicles (0.5 mM
lipid) and corrected as described in reference 3. In both assays,
lipid-peptide mixtures were incubated at 37°C for 10 min before data
acquisition. In all peptide binding and insertion assays, a low
peptide-to-lipid ratio (1:500) was used so that the amount of free
peptide would not significantly interfere with the analysis of the
experimental results.
 |
RESULTS |
Figure 1A displays the three
sequences that were used in this work as representative of the proposed
Ebola virus fusion peptide. The sequence of the fusion peptide,
initially described by Volchkov et al. (39) and Feldmann et
al. (8) and whose putative fusogenic character was put
forward by Gallaher (12), consists of a stretch of 16 hydrophobic and uncharged amino acids which is flanked by two
negatively charged Glu residues. According to the interfacial hydrophobicity scale determined by Wimley and White (44),
Glu shows the lowest tendency to partitioning into the bilayer.
Therefore, even if the overall interfacial hydrophobicity of the
sequence is comparable to that of the HIV-1 fusion peptide (Fig. 1B),
flanking Glu residues in the Ebola virus sequence are unlikely to
partition into the interface and penetrate into the hydrophobic core of the membrane. This fact prompted us to assess the effect of Glu residues when they are located either at the N terminus, at the C
terminus, or at both ends of the sequence. As described below, experimental results in this work indicate that peptide-membrane interaction is severely impaired by Glu located at the N terminus.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Sequences of the three Ebola GP peptides studied in
this work. Positions of Glu (squares) and Trp (circles) residues and
the canonical fusion tripeptide (underlined) are indicated. (B)
Hydropathy plots for the fusion peptides of Ebola virus
(EBOEE) and HIV-1 (HIVarg
[26]). A window of 5 amino acids was used with the
hydrophobicity scale at membrane interfaces as described by Wimley and
White (44).
|
|
We first assessed the putative fusogenicities of these sequences in a
model system. LUV composed of PC, PE, CHOL, and PI (2:1:1:0.5 molar
ratio) were selected as membrane targets. As discussed in the
introduction, this mixture of lipids roughly mimics the lipid composition of the hepatocyte plasma membrane (18). As shown in Fig. 2, when added to a PC-PE-CHOL-PI
vesicle suspension, the EBOGE peptide was able to induce
fusion, detected as the mixing of the vesicular membranes. Figure 2A
shows that the fusion activity of the peptide could be detected only in
the presence of calcium. The cation effect was not dependent on the
order of addition; i.e., fusion could be observed when addition of the
cation preceded that of the peptide and also when the cation was added
after the peptide. The results displayed in Fig. 2B demonstrate that
the observed fusion activity was dependent on the presence of PI in the
lipidic mixture. Moreover, this phospholipid could not be replaced by
other anionic phospholipids such as PG or PA, indicating that the PI
effect is not due merely to its electrostatic charge. The acyl chain
composition did not appear to be critical, since PI from bovine liver
or plant origin sustained the fusion process to the same extent (data
not shown). Table 1 summarizes the fusion data obtained with different vesicles as targets. Taken together, the
data confirm that PI is necessary for the fusion process. In addition,
it can be deduced that both LUV and SUV can be readily fused by the
peptide in a PI-dependent fashion.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Ebola virus fusion peptide (EBOGE)-induced
LUV fusion. The peptide was added at the times indicated by the arrows
to PC-PE-CHOL-PI (2:1:1:0.5) LUV suspensions (0.1 mM) at a
peptide-to-lipid ratio of 1:1.5. (A) Influence of calcium. Trace a,
sample containing both calcium (10 mM) and peptide; trace b, control
without calcium. (B) Influence of bilayer composition. Molar ratios:
trace a, PC-PE-CHOL-PI, 2:1:1:0.5; trace b, PC-PE-CHOL, 2:1:1; trace c,
PC-PE-CHOL-PG, 2:1:1:0.5; trace d, PC-PE-CHOL-PA, 2:1:1:0.5.
|
|
The fusion capacities of the three peptides under study are compared in
Fig. 3. The results reveal that all three
sequences induced fusion in a dose-dependent manner and that
EBOGE was more efficient than EBOEE and
EBOEA sequences. This observation suggests that a negative
net charge or a polar residue at the peptide N terminus somehow hinders
the membrane fusion process. However, net charge might not be the only
cause of the impairing effect exerted by the Glu residue. Experiments
conducted at pH 4.5 indicate that the fusion process mediated by the
three sequences was not influenced by the low pH (data not shown).

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
Influence of the terminal sequence on Ebola virus fusion
peptide-induced liposome fusion. (A) Kinetics of fusion as a function
of time. Peptides were added at the time indicated by the arrow to
PC-PE-CHOL-PI (2:1:1:0.5) LUV suspensions (0.1 mM) at a
peptide-to-lipid ratio of 1:1.5. (B) Extents of fusion (NBD
fluorescence after 10 min) as a function of increasing concentrations
of Ebola virus fusion peptides. The vesicle concentration was 0.1 mM in
all cases. , EBOGE; , EBOEA; ,
EBOEE.
|
|
A decreased binding of the peptide to the vesicles could be at the
origin of the lack of fusion detected in the absence of PI or could be
the cause of the reduced fusion activity observed for the sequences
bearing Glu at the N terminus. Therefore, we decided to estimate the
amount of peptide bound to vesicles and the depth of its penetration
into the membrane. To that end, we made use of the single Trp
fluorescent residue existing in the sequences (Fig. 1A). For these
experiments we employed SUV as targets, since they interfere less than
LUV with the fluorescence measurements because of their low
light-scattering properties. We also selected the simplest vesicle
composition supporting fusion that was suitable for carrying out the
penetration assays (PC-PI, 1:2 molar ratio).
Figure 4 illustrates the binding
capacities of the three sequences as detected through changes in the
intrinsic peptide fluorescence emission. Trp emission for
EBOGE changed significantly in the presence of PC-PI SUV
(Fig. 4A). The emission intensity was enhanced and the maximum was
shifted to a lower wavelength, from 351 to 348 nm. Both effects suggest
that the Trp residue in the presence of PC-PI vesicles senses a less
polar environment, which is indicative of binding to and subsequent
penetration of the peptide into the hydrophobic core of the bilayer. In
contrast, in the presence of PC SUV, EBOGE Trp emission did
not change significantly. EBOEA and EBOEE Trp
emissions show only a very small increase in the presence of PC-PI
vesicles (Fig. 4B and C). The fact that the Trp emission fluorescence
changed little in the latter samples could be a consequence of the lack
of peptide association to vesicles or of a surface binding phenomenon
that would not imply changes in the polarity of the Trp environment. We
therefore complemented these observations with binding results obtained
by two other methods. First, unbound peptide was physically separated
from peptide bound to the vesicles by centrifugation and subsequently was quantitated in supernatants. Second, we also measured partitioning in the intact system. To that end we employed an assay based on the
quenching of Trp fluorescence by TNP-PE incorporated into vesicles. The
TNP headgroup quenches by such a long range that, in principle,
quenching is observed for Trp residues inserted at any level in the
bilayer (16). The data obtained by the three methods used to
estimate binding correlate very well (Table
2). Maximum binding was found by all
three methods to occur for EBOGE peptide and PC-PI
vesicles. The results in Table 2 further indicate that under the same
conditions, EBOEA and EBOEE peptides bound to
vesicles to a lesser extent. This limited binding could be the cause
for the reduced fusion induced by these sequences (Fig. 2). From the
results in Table 2 it can also be concluded that EBOGE
hardly bound to pure PC vesicles. Again, this phenomenon could be
correlated to the absence of fusion when PC vesicles are used as
targets for this peptide (Table 1). The presence of 10 mM
Ca2+ in the samples did not affect the binding capacity of
the peptides in any of the samples; e.g., under conditions similar to
those for Table 2, EBOGE displayed a 
max
of 4.4 nm and a fluorescence intensity of 1.30, while the effect of
EBOEE was clearly smaller, with a 
max of
2.2 nm and an intensity of 1.14.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 4.
Fluorescence emission spectra of EBOGE (A),
EBOEA (B), and EBOEE (C) in buffer and
incubated with SUV (0.5 mM). Spectra: 1, buffer alone; 2, PC-PI (1:2)
SUV; 3, PC SUV. The peptide-to-lipid ratio was 1:500.
|
|
Finally, the results displayed in Fig. 5
and Table 3 prove that the Ebola virus
fusion peptide penetrates into the membrane to the level of the acyl
chains in the presence of PI. The experiments illustrated in Fig.
5 were carried out to determine the location of fusogenic
EBOGE-Trp in the vesicle bilayer. In Fig. 5A emission spectra of SUV containing d-DHPE are displayed. The spectra were acquired in the presence of increasing amounts of EBOGE
with the excitation wavelength set at 280 nm. The results demonstrate
that peptide addition does not affect significantly the d-DHPE
fluorescence under those conditions. This would mean that the Trp
residue is unable to effectively transfer energy by resonance to this
surface-residing group. However, both Br6-PSPC and
Br11-PSPC efficiently quenched EBOGE-Trp
fluorescence (Fig. 5B). Bromine atoms quench by a short-range process
that requires a close approach to the fluorophore (3). Consequently, the Trp residue must be located close to the quenchers in
the hydrophobic matrix of the bilayer.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 5.
Depth of penetration into the bilayer of the
EBOGE Trp residue. (A) Fluorescence emission spectra of
PC-PI-d-DHPE (1:2:0.19) SUV (0.25 mM) incubated with increasing
amounts of EBOGE. Spectra: 1, SUV alone; 2, peptide-to-lipid ratio of 1:250; 3, peptide-to-lipid ratio of 1:125.
Dashed line, positive control containing the colicin A thermolytic
fragment surface bound to PG SUV (for comparison, the emission spectrum
of SUV alone in this sample was normalized to spectrum 1). (B)
Fluorescence emission spectra of EBOGE incubated with SUV
(0.5 mM) containing brominated phospholipids. Spectra: 1, buffer alone;
2, PC-PI (1:2) SUV; 3, Br6-PSPC-PI (1:2) SUV; 4, Br11-PSPC-PI (1:2) SUV. The peptide-to-lipid ratio was
1:500.
|
|
Table 3 summarizes the results obtained by the two methods, i.e., use
of d-DHPE and brominated lipids, for the three peptides and for
EBOGE in the presence of PC vesicles. d-DHPE fluorescence was unaffected in the presence of any of the peptides. Nevertheless, peptide fluorescence was quenched by the bromolipids. The results indicate that for the three peptides interacting with PC-PI vesicles and for EBOGE in the presence of PC vesicles, the quenching
effect parallels the extent of binding (Table 2). In the absence of PI
in the target vesicle, even the most binding-competent
EBOGE sequence is unable to associate with and penetrate
into the vesicle bilayer.
For bilayer and hydrocarbon chain region thickness of
50 and 30 Å,
respectively, McIntosh and Holloway (21) determined the
bromine distances from the bilayer center to be 11 Å for 6,7 labels
and 6.5 Å for 11,12 labels. The Förster distances
(R0) for energy transfer estimated for these
labels,
6 to 9 Å (1, 3), would allow quenching of Trp
residues immersed in the methylene chain region of the bilayer. On the
other hand, the dansyl moiety in the d-DHPE probe is probably located
at the edge of the lipid-water interface in the vesicles. Given that
the R0 distance calculated for the couple
dansyl-Trp is approximately 17 Å (36), quenching of Trp
fluorescence should have been observed if this residue remained
associated with the interface and/or with the acyl chain region close
to it. We can conclude that in the peptide population bound to the
vesicles (Table 2), Trp fluorescence is completely quenched when
bromolipid-containing vesicles are used as targets and, therefore, that
these residues must be buried deep into the hydrophobic core of the
bilayer, far from the vesicle surface, under conditions in which the
peptide is fusion competent.
 |
DISCUSSION |
Our results in this work show that the Ebola virus putative fusion
peptide is able to interact with lipid vesicles and destabilize them in
the direction of membrane fusion. These observations imply that if, as
a consequence of the activation of Ebola virus fusion process, the
fusion peptide is exposed to the aqueous medium, this protein sequence
would actually be capable of partitioning into a target membrane. This
behavior is identical to that found for various sequences arising from
different enveloped viruses that have been proposed to act as fusion
peptides (7, 15, 19, 25-29). Moreover, our results also
demonstrate that this sequence would not act as an inert anchor of the
spike to the target membrane; rather, the peptide ability to induce
fusion indicates that when effectively bound to membranes, this
sequence might be involved in the induction of some kind of bilayer
perturbation leading to fusion. Taken together, our findings therefore
support the implication of this sequence in Ebola virus fusion.
The fusion activity of the Ebola virus peptide could be observed only
in the presence of calcium. The fact that the cation did not influence
the binding process or the depth of penetration of the bound peptides
implies that its action must be confined to the fusion process itself.
The molecular mechanism behind this phenomenon is not clear at the
moment. The combined action of the cation and the peptide could be due
to a specific interaction between both of them or else could be the
result of an electrostatic effect, namely, the neutralization of the
peptide net charge, that would help bring about the peptide-induced
fusion process. The joint requirement of calcium ions and PI could even
suggest the implication of a PI-Ca-Glu salt bridge. Several studies are under way in our laboratory to discern among these possibilities.
A specific feature of Ebola virus peptide-induced fusion that
distinguishes this process from other so-far-described liposome fusion
events induced by fusion peptides is its dependence on the presence of
a particular phospholipid, PI, in the target vesicles. According to our
experimental results, PI is necessary for the initial association of
the peptide to the vesicles. The interfacial hydrophobicity values for
the Ebola virus fusion peptide (Fig. 1B) indicate a general tendency
for partitioning into electrically neutral zwitterionic phospholipid
membranes (44). However, our results demonstrate that the
peptide does not partition into neutral interfaces unless PI is
included in the membrane composition. Several facts argue against the
existence of a purely electrostatic interaction at the origin of this
effect. The only residues containing net charged side chains in the
sequence are the negatively charged Glu residues. It seems unlikely
that the anionic PI in vesicles would promote peptide interaction at
neutral pH. Moreover, other anionic phospholipids at neutral pH, such
as PA or PG, could not sustain the fusion process. Finally, the high
ionic strength used in the experiments, which is close to the
physiological values in serum, would also weaken putative electrostatic
interactions between the sequences and charged vesicle surfaces.
Among the possible explanations for the PI effect detected in our
system is that PI might be involved in inducing some kind of change in
the physical properties of the bulk membrane, other than altering the
vesicle surface charge, that would be necessary for peptide
association. However, there are no indications of any such physical
properties specific to PI. Alternatively, there might exist a specific
interaction of the peptide with this particular phospholipid, and, as
mentioned above, calcium ions could be involved in this phenomenon. The
existence of stereospecific interactions has been invoked to explain
the ceramide dependence of the Semliki Forest virus fusion with
membranes (22, 24). Vesicular stomatitis virus also binds
preferentially to phosphatidylserine (31), and the fusogenic
activity of the reconstituted fusion protein depends on the presence of
this lipid in the target vesicles (6). In addition to their
structural function in membranes, inositol lipids are well known
because they play specific roles in cell signalling (33) and
membrane protein anchoring (9). Several findings involve
this class of lipids in viral entry and infectivity as well.
Stimulation of certain viral receptors results in the activation of
signal transduction pathways involving the enzyme PI 3-kinase
(32). It has also been suggested that glycan PI hydrolysis
might be involved in the initiation of HIV-1 replication (20). Just recently, it has been found that envelope PI is
essential for a correct epitope presentation to neutralizing antibodies in African swine fever virions (14).
Our results also indicate that the N-terminal composition might be a
limiting factor for the destabilizing interaction of this sequence with
membranes. Glu residues at the N terminus appear to interfere with the
initial interaction of the peptide with vesicles. A correct residue at
the fusion peptide N terminus appears to be crucial for the fusogenic
function of certain spike proteins (10, 34). We have
reported that a polar substitution, Val2xGlu, in the HIV-1 fusion
peptide renders a sequence unable to induce liposome fusion
(26-28). However, the Glu effect in the case of the HIV-1
peptide seems to be different, since this residue does not interfere
with binding to or penetration into the vesicle bilayer
(26). Moreover, the three peptides used in this study are
representative of the correct putative Ebola virus fusion sequence
(12). Therefore, our results should be taken as indicative of the mechanism of action of the correct sequence within the wild-type
protein. The fact that even the bound sequences containing Glu at the N
terminus were also able to insert and induce some vesicle fusion points
to the internal amino acid sequence as the promoter of the fusogenic
activity. Given the sequence homology with the Rous sarcoma virus
transmembrane protein, it is also likely that Ebola GP contains the
fusion peptide in internal regions of the glycoprotein (12, 40,
41). If this is the case, we conclude that masking the Glu
residue located at the N terminus would optimize the partition of the
putative fusogenic sequence into the target membrane. It should also be
noted that our experiments are designed for detecting a maximum of
membrane fusion. Under physiological conditions, however, what is seen
here as an impairment of fusion could be beneficial for viral
replication, e.g., by avoidance of cell-cell fusion.
Investigations of synthetic fusion peptides and model membranes have
delineated the structural requirements of these sequences and their
membrane activities (7, 15, 19, 25-29). In addition, it has
recently been demonstrated for the HIV-1 fusion peptide that its
lipid-mixing activity measured in vitro is sensitive to factors of
physiological relevance during the virus entry into host cells
(27). Those findings could open the possibility of using in
vitro assays for assessing in an easy manner the potencies of antiviral
agents targeted to these sequences; this would stress the importance of
studies using model systems. Taking into account the strict lipid
dependence for the fusion peptide-induced fusion event detected here,
our observations might in the future be important in the design of
specific therapeutic approaches for the treatment of Ebola
virus-infected individuals.
 |
ACKNOWLEDGMENTS |
We thank J. M. González-Mañas for helpful
discussions and for the provision of colicin A (thermolytic fragment).
This work was supported by the EC Concerted Action Programme
"Interaction of HIV Proteins with Cell Membranes," the Basque Government (PI 94-53; PI 96-46), and the University of the Basque Country (UPV 042.310-EA085/97).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Departamento de
Bioquímica, Universidad del País Vasco, Aptdo. 644, 48080 Bilbao, Spain. Phone: 34 4 4647700, ext. 2378. Fax: 34 4 4648500. E-mail: GBPNIESJ{at}lg.ehu.es.
 |
REFERENCES |
| 1.
|
Abrams, F. S., and E. London.
1992.
Calibration of the parallax fluorescence quenching method for determination of membrane penetration depth: refinement and comparison of quenching by spin-labeled and brominated lipids.
Biochemistry
31:5312-5322[Medline].
|
| 2.
|
Alonso, A.,
R. Saez,
A. Villena, and F. M. Goñi.
1982.
Increase in size of sonicated phospholipid vesicles in the presence of detergents.
J. Membr. Biol.
67:55-62[Medline].
|
| 3.
|
Bolen, E. J., and P. W. Holloway.
1990.
Quenching of tryptophan fluorescence by brominated phospholipid.
Biochemistry
29:9638-9643[Medline].
|
| 4.
|
Böttcher, C. S. F.,
C. M. van Gent, and C. Fries.
1961.
A rapid and sensitive sub-micro phosphorus determination.
Anal. Chim. Acta
24:203-204.
|
| 5.
|
Carr, C., and P. S. Kim.
1993.
A spring-loaded mechanism for the conformational change of Influenza hemagglutinin.
Cell
73:823-832[Medline].
|
| 6.
|
Eidelman, O.,
R. Schlegel,
T. S. Tralka, and R. Blumenthal.
1984.
pH-dependent fusion induced by vesicular stomatitis virus glycoprotein reconstituted into phospholipid vesicles.
J. Biol. Chem.
259:4622-4628[Abstract/Free Full Text].
|
| 7.
|
Epand, R. M.,
J. Cheetham,
P. F. Epand,
P. L. Yeagle,
C. D. Richardson, and W. F. DeGrado.
1992.
Peptide models for the membrane destabilizing actions of viral fusion proteins.
Biopolymers
32:309-314[Medline].
|
| 8.
|
Feldmann, H.,
H. D. Klenk, and A. Sanchez.
1993.
Molecular biology and evolution of filoviruses.
Arch. Virol. Suppl.
7:81-100[Medline].
|
| 9.
|
Ferguson, M. A. J., and A. F. Williams.
1988.
Cell surface anchoring of proteins via glycosylphosphatidylinositol structures.
Annu. Rev. Biochem.
57:285-320[Medline].
|
| 10.
|
Freed, E. O.,
E. L. Delwart,
G. L. Buchschacher, and A. T. Panganiban.
1992.
A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity.
Proc. Natl. Acad. Sci. USA
89:70-74[Abstract/Free Full Text].
|
| 11.
|
Gallaher, W. R.
1987.
Detection of a fusion peptide sequence in the transmembrane protein of the human immunodeficiency virus.
Cell
50:327-328[Medline].
|
| 12.
|
Gallaher, W. R.
1996.
Similar structural models of the transmembrane proteins of Ebola and avian sarcoma viruses.
Cell
85:477-478[Medline].
|
| 13.
|
Gilbert, G. E.,
B. C. Furie, and B. Furie.
1990.
Binding of human factor VIII to phospholipid vesicles.
J. Biol. Chem.
265:815-822[Abstract/Free Full Text].
|
| 14.
|
Gómez-Puertas, P.,
J. M. Oviedo,
F. Rodríguez,
J. Coll, and J. M. Escribano.
1997.
Neutralization susceptibility of African swine fever virus is dependent on the phospholipid composition of viral particles.
Virology
228:180-189[Medline].
|
| 15.
|
Gray, C.,
S. A. Tatulian,
S. A. Wharton, and L. K. Tamm.
1996.
Effect of the N-terminal glycine on the secondary structure, orientation and interaction of the influenza hemagglutinin fusion peptide with lipid bilayers.
Biophys. J.
70:2275-2286[Medline].
|
| 16.
|
Heymann, J. B.,
S. D. Zakharov,
Y. L. Zhang, and W. A. Cramer.
1996.
Characterization of electrostatic and nonelectrostatic components of protein-membrane binding interactions.
Biochemistry
35:2717-2725[Medline].
|
| 17.
|
Hope, M. J.,
M. B. Bally,
G. Webb, and P. R. Cullis.
1985.
Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential.
Biochim. Biophys. Acta
812:55-65.
|
| 18.
|
Jain, M. K.
1988.
.
Introduction to biological membranes, 2nd ed.
John Wiley & Sons, New York, N.Y.
|
| 19.
|
Lear, J. D., and W. F. DeGrado.
1987.
Membrane binding and conformational properties of peptides representing the NH2 terminus of influenza HA-2.
J. Biol. Chem.
262:2500-2505.
|
| 20.
|
Leung, D. W.,
P. K. Peterson,
R. Weeks,
G. Gekker,
C. C. Chao,
A. H. Kaplan,
N. Balantac,
C. Tompkins,
G. E. Underiner,
S. Bursten,
W. Harris,
J. A. Bianco, and J. W. Singer.
1995.
CT-2576, an inhibitor of phospholipid signaling, suppresses constitutive and induced expression of human immunodeficiency virus.
Proc. Natl. Acad. Sci. USA
92:4813-4817[Abstract/Free Full Text].
|
| 21.
|
McIntosh, T. J., and P. W. Holloway.
1987.
Determination of the depth of bromine atoms in bilayers formed from bromolipid probes.
Biochemistry
26:1783-1788[Medline].
|
| 22.
|
Moesby, L.,
J. Corver,
R. K. Erukulla,
R. Bittman, and J. Wilschut.
1995.
Sphingolipids activate membrane fusion of Semliki Forest virus in a stereospecific manner.
Biochemistry
34:10319-10324[Medline].
|
| 23.
|
Murphy, F. A.,
M. P. Kiley, and S. P. Fisher-Hoch.
1990.
Filoviridae. Marburg and Ebola viruses, p. 933-942. In
B. N. Fields, D. M. Knipe, et al. (ed.), Virology.
Raven Press, New York, N.Y.
|
| 24.
|
Nieva, J. L.,
R. Bron,
J. Corver, and J. Wilschut.
1994.
Membrane fusion of Semliki Forest virus requires sphingolipids in the target membrane.
EMBO J.
13:2797-2804[Medline].
|
| 25.
|
Nieva, J. L.,
S. Nir,
A. Muga,
F. M. Goñi, and J. Wilschut.
1994.
Interaction of the HIV-1 fusion peptide with phospholipid vesicles: Different structural requirements for leakage and fusion.
Biochemistry
33:3201-3209[Medline].
|
| 26.
|
Pereira, F. B.,
F. M. Goñi,
A. Muga, and J. L. Nieva.
1997.
Permeabilization and fusion of uncharged lipid vesicles induced by the HIV-1 fusion peptide adopting an extended conformation: dose and sequence effects.
Biophys. J.
73:1977-1986[Medline].
|
| 27.
|
Pereira, F. B.,
F. M. Goñi, and J. L. Nieva.
1997.
Membrane fusion induced by the HIV type 1 fusion peptide: modulation by factors affecting glycoprotein 41 activity and potential anti-HIV compounds.
AIDS Res. Hum. Retroviruses
13:1203-1211[Medline].
|
| 28.
|
Pereira, F. B.,
F. M. Goñi, and J. L. Nieva.
1995.
Liposome destabilization induced by the HIV-1 fusion peptide. Effect of a single amino acid substitution.
FEBS Lett.
362:243-246[Medline].
|
| 29.
|
Rafalski, M.,
J. Lear, and W. F. DeGrado.
1990.
Phospholipid interactions of synthetic peptides representing the N-terminus of HIV gp41.
Biochemistry
29:7917-7922[Medline].
|
| 30.
|
Sanchez, A.,
S. G. Trappier,
B. W. J. Mahy,
C. J. Peters, and S. T. Nichol.
1996.
The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing.
Proc. Natl. Acad. Sci. USA
93:3602-3607[Abstract/Free Full Text].
|
| 31.
|
Schlegel, R.,
T. S. Tralka,
M. C. Willingham, and I. Pastan.
1983.
Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site?
Cell
32:639-646[Medline].
|
| 32.
|
Sinclair, A. J., and P. J. Farrell.
1995.
Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus.
J. Virol.
69:5461-5468[Abstract].
|
| 33.
|
Spiegel, S.,
D. Foster, and R. Kolesnick.
1996.
Signal transduction through lipid second messengers.
Curr. Opin. Cell. Biol.
8:159-167[Medline].
|
| 34.
|
Steinhauer, D. A.,
S. A. Wharton,
J. J. Skehel, and D. C. Wiley.
1995.
Studies of the membrane fusion activities of fusion peptide mutants of influenza virus hemagglutinin.
J. Virol.
69:6643-6651[Abstract].
|
| 35.
|
Struck, D. K.,
D. Hoekstra, and R. E. Pagano.
1981.
Use of resonance energy transfer to monitor membrane fusion.
Biochemistry
20:4093-4099[Medline].
|
| 36.
|
Vaz, W. L. C., and G. Schoellmann.
1976.
A fluorescence study on some specifically modified derivatives of chymotrypsin, trypsin and subtilisin.
Biochim. Biophys. Acta
439:206-218[Medline].
|
| 37.
|
Volchkov, V.,
V. Volchkova,
C. Eckel,
H.-D. Klenk,
M. Bouloy,
B. Leguenno, and H. Feldmann.
1997.
Emergence of subtype Zaire Ebola virus in Gabon.
Virology
232:139-144[Medline].
|
| 38.
|
Volchkov, V. E.,
S. Becker,
V. A. Volchkova,
V. A. Ternovoj,
A. N. Kotov,
S. V. Netesov, and H. D. Klenk.
1995.
GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and Vaccinia virus polymerases.
Virology
214:421-430[Medline].
|
| 39.
|
Volchkov, V. E.,
V. M. Blinov, and S. V. Netesov.
1992.
The envelope glycoprotein of Ebola virus contains an immunosuppressive-like domain similar to oncogenic retroviruses.
FEBS Lett.
305:181-184[Medline].
|
| 40.
|
White, J.
1990.
Viral and cellular membrane fusion proteins.
Annu. Rev. Physiol.
52:675-697[Medline].
|
| 41.
|
White, J.
1992.
Membrane fusion.
Science
258:917-923[Abstract/Free Full Text].
|
| 42.
|
White, J., and A. Helenius.
1980.
pH-dependent fusion between the Semliki Forest virus membrane and liposomes.
Proc. Natl. Acad. Sci. USA
77:3273-3277[Abstract/Free Full Text].
|
| 43.
|
Wild, C.,
J. W. Dubay,
T. Greenwell,
T. Baird,
T. G. Oas,
C. McDanal,
E. Hunter, and T. Matthews.
1994.
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex.
Proc. Natl. Acad. Sci. USA
91:12676-12680[Abstract/Free Full Text].
|
| 44.
|
Wimley, W., and S. H. White.
1996.
Experimentally determined hydrophobicity scale for proteins at membrane interfaces.
Nat. Struct. Biol.
3:842-848[Medline].
|
J Virol, March 1998, p. 1775-1781, Vol. 72, No. 3
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Freitas, M. S., Gaspar, L. P., Lorenzoni, M., Almeida, F. C. L., Tinoco, L. W., Almeida, M. S., Maia, L. F., Degreve, L., Valente, A. P., Silva, J. L.
(2007). Structure of the Ebola Fusion Peptide in a Membrane-mimetic Environment and the Interaction with Lipid Rafts. J. Biol. Chem.
282: 27306-27314
[Abstract]
[Full Text]
-
Lorizate, M., Cruz, A., Huarte, N., Kunert, R., Perez-Gil, J., Nieva, J. L.
(2006). Recognition and Blocking of HIV-1 gp41 Pre-transmembrane Sequence by Monoclonal 4E10 Antibody in a Raft-like Membrane Environment. J. Biol. Chem.
281: 39598-39606
[Abstract]
[Full Text]
-
Kuhn, J. H., Radoshitzky, S. R., Guth, A. C., Warfield, K. L., Li, W., Vincent, M. J., Towner, J. S., Nichol, S. T., Bavari, S., Choe, H., Aman, M. J., Farzan, M.
(2006). Conserved Receptor-binding Domains of Lake Victoria Marburgvirus and Zaire Ebolavirus Bind a Common Receptor. J. Biol. Chem.
281: 15951-15958
[Abstract]
[Full Text]
-
Perez-Romero, P., Fuller, A. O.
(2005). The C Terminus of the B5 Receptor for Herpes Simplex Virus Contains a Functional Region Important for Infection. J. Virol.
79: 7431-7437
[Abstract]
[Full Text]
-
Sainz, B. Jr., Rausch, J. M., Gallaher, W. R., Garry, R. F., Wimley, W. C.
(2005). Identification and Characterization of the Putative Fusion Peptide of the Severe Acute Respiratory Syndrome-Associated Coronavirus Spike Protein. J. Virol.
79: 7195-7206
[Abstract]
[Full Text]
-
Gerber, D., Pritsker, M., Gunther-Ausborn, S., Johnson, B., Blumenthal, R., Shai, Y.
(2004). Inhibition of HIV-1 Envelope Glycoprotein-mediated Cell Fusion by a DL-Amino Acid-containing Fusion Peptide: POSSIBLE RECOGNITION OF THE FUSION COMPLEX. J. Biol. Chem.
279: 48224-48230
[Abstract]
[Full Text]
-
Adam, B., Lins, L., Stroobant, V., Thomas, A., Brasseur, R.
(2004). Distribution of Hydrophobic Residues Is Crucial for the Fusogenic Properties of the Ebola Virus GP2 Fusion Peptide. J. Virol.
78: 2131-2136
[Abstract]
[Full Text]
-
Jeffers, S. A., Sanders, D. A., Sanchez, A.
(2002). Covalent Modifications of the Ebola Virus Glycoprotein. J. Virol.
76: 12463-12472
[Abstract]
[Full Text]
-
Empig, C. J., Goldsmith, M. A.
(2002). Association of the Caveola Vesicular System with Cellular Entry by Filoviruses. J. Virol.
76: 5266-5270
[Abstract]
[Full Text]
-
Feldmann, H., Volchkov, V. E., Volchkova, V. A., Stroher, U., Klenk, H.-D.
(2001). Biosynthesis and role of filoviral glycoproteins. J. Gen. Virol.
82: 2839-2848
[Full Text]
-
Watanabe, S., Takada, A., Watanabe, T., Ito, H., Kida, H., Kawaoka, Y.
(2000). Functional Importance of the Coiled-Coil of the Ebola Virus Glycoprotein. J. Virol.
74: 10194-10201
[Abstract]
[Full Text]
-
Suárez, T., Gallaher, W. R., Agirre, A., Goñi, F. M., Nieva, J. L.
(2000). Membrane Interface-Interacting Sequences within the Ectodomain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein: Putative Role during Viral Fusion. J. Virol.
74: 8038-8047
[Abstract]
[Full Text]
-
Delos, S. E., Gilbert, J. M., White, J. M.
(2000). The Central Proline of an Internal Viral Fusion Peptide Serves Two Important Roles. J. Virol.
74: 1686-1693
[Abstract]
[Full Text]
-
Ito, H., Watanabe, S., Sanchez, A., Whitt, M. A., Kawaoka, Y.
(1999). Mutational Analysis of the Putative Fusion Domain of Ebola Virus Glycoprotein. J. Virol.
73: 8907-8912
[Abstract]
[Full Text]
-
Sanchez, A., Yang, Z.-Y., Xu, L., Nabel, G. J., Crews, T., Peters, C. J.
(1998). Biochemical Analysis of the Secreted and Virion Glycoproteins of Ebola Virus. J. Virol.
72: 6442-6447
[Abstract]
[Full Text]